Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097284 | 0.84 | PKM (0.41) | TSHRALDH1A1MAPT | |
| SCHEMBL15829477 | 0.81 | TSHR (0.35) | DGAT1TSHRALDH1A1 | |
| Pivalate SCHEMBL29716693 | 0.77 | DGAT1 (0.44) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL1661824 | 0.77 | DGAT1 (0.44) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL1010735 | 0.77 | DGAT1 (0.56) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL1425286 | 0.74 | DGAT1 (0.42) | DGAT1TSHRALDH1A1KCNN4SRC | |
| Hydrochloric Acid SCHEMBL10829675 | 0.74 | DGAT1 (0.54) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL4070809 | 0.74 | ALDH1A1 (0.45) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL28803702 | 0.74 | DGAT1 (0.54) | DGAT1TSHRALDH1A1KCNN4SRC | |
| SCHEMBL30440750 | 0.74 | DGAT1 (0.54) | DGAT1TSHRALDH1A1KCNN4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372300-B2 | Additives for electrolyte solution and electrolyte solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2013-02-12 | — | — | US | claimed |
| EP-2037468-B1 | ADDITIVE FOR ELECTROLYTE SOLUTION AND ELECTROLYTE SOLUTION | OTSUKA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | claimed |
| US-20120170172-A1 | ADDITIVES FOR ELECTROLYTE SOLUTION AND ELECTROLYTE SOLUTION | OKA AKINORI (JP) | 2012-07-05 | — | — | US | claimed |
| US-8163195-B2 | Additives for electrolyte solution and electrolyte solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | claimed |
| US-20090309060-A1 | Additives for Electrolyte Solution and Electrolyte Solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2009-12-17 | — | — | US | claimed |
| CN-101479818-A | Additive for electrolyte and electrolyte | OTSUKA CHEMICAL CO LTD (JP) | 2009-07-08 | — | — | CN | claimed |
| EP-2037468-A1 | ADDITIVE FOR ELECTROLYTE SOLUTION AND ELECTROLYTE SOLUTION | Otsuka Chemical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | claimed |
| CN-116457399-A | Adhesion of particles containing foaming agent based on polyimide or polyacrylate | 赢创运营有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8372300-B2 | Additives for electrolyte solution and electrolyte solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-2037468-B1 | ADDITIVE FOR ELECTROLYTE SOLUTION AND ELECTROLYTE SOLUTION | OTSUKA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| CN-101479818-B | Additive for electrolyte and electrolyte | OTSUKA CHEMICAL CO LTD | 2012-10-17 | — | — | CN | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8163195-B2 | Additives for electrolyte solution and electrolyte solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090309060-A1 | Additives for Electrolyte Solution and Electrolyte Solution | OTSUKA CHEMICAL CO., LTD. (JP) | 2009-12-17 | — | — | US | disclosed |
| CN-101479818-A | Additive for electrolyte and electrolyte | OTSUKA CHEMICAL CO LTD (JP) | 2009-07-08 | — | — | CN | disclosed |
| EP-2037468-A1 | ADDITIVE FOR ELECTROLYTE SOLUTION AND ELECTROLYTE SOLUTION | Otsuka Chemical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | DGAT1 2352/4885TSHR 1109/4885ALDH1A1 4132/4885 |
| US-20090309060-A1 | Additives for Electrolyte Solution and Electrolyte Solution | SLC9A1, SLC26A3, AQP1 | DGAT1 2888/4885TSHR 4478/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.